Early Access

Back to JNJ

JOHNSON & JOHNSON Cash & Equivalents 2006-2025 | JNJ

Beta

What is cash & equivalents?

Cash and cash equivalents can be defined as the most liquid assets on a company's balance sheet, including cash on hand and short-term investments maturing within 90 days.

What is JOHNSON & JOHNSON's current cash & equivalents?

JOHNSON & JOHNSON (JNJ) annual cash & equivalents for 2025 was $19.71B, a 18.24% decline from 2024. JOHNSON & JOHNSON cash & equivalents for the quarter ending December 28, 2025 was $19.71B.

What was JOHNSON & JOHNSON's cash & equivalents in 2024?

JOHNSON & JOHNSON annual cash & equivalents for 2024 was $24.11B, a 10.27% increase from 2023.

What was JOHNSON & JOHNSON's cash & equivalents in 2023?

JOHNSON & JOHNSON annual cash & equivalents for 2023 was $21.86B, a 26.32% increase from 2019.

What is JOHNSON & JOHNSON's 2-year cash & equivalents CAGR?

JOHNSON & JOHNSON cash & equivalents grew at a compound annual growth rate (CAGR) of 5.05% from FY2023 to FY2025, going from $21.86B to $19.71B over 2 years.

Cash & Equivalents History

Year-over-year comparison from 10-K annual reports

Key Statistics
Trend Direction
Stable
CAGR+2.0%
FY2017
$17.82B
FY2025
$19.71B
060708121314171819232425
5 years selected
Cash & Equivalents History
PeriodValueChangeSource
FY2025$19.71B-18.2%10-K
FY2024$24.11B+10.3%10-K
FY2023$21.86B+26.3%10-K
FY2019$17.30B-4.4%10-K
FY2018$18.11B+1.6%10-K
FY2017$17.82B+22.7%10-K
FY2014$14.52B-30.6%10-K
FY2013$20.93B+40.3%10-K
FY2012$14.91B+38.5%10-K
FY2008$10.77B+38.6%10-K
FY2007$7.77B+90.3%10-K
FY2006$4.08B-10-K
Company: JOHNSON & JOHNSONTicker: JNJSector: HealthcareIndustry: Pharmaceutical PreparationsView company profile →